{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T14:22:36Z","timestamp":1783520556580,"version":"3.55.0"},"reference-count":39,"publisher":"Ovid Technologies (Wolters Kluwer Health)","license":[{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n                    <jats:title>KEY POINTS<\/jats:title>\n                    <jats:p>\n                      <jats:bold>What is already known<\/jats:bold>\n                    <\/jats:p>\n                    <jats:p>Cyclosporine A (CsA) is widely used for immunosuppression after hematopoietic stem cell transplantation (HSCT), but its narrow therapeutic window and marked pharmacokinetic variability make pediatric patients particularly vulnerable to drug-induced liver injury (DILI).<\/jats:p>\n                    <jats:p>\n                      <jats:bold>What this study adds<\/jats:bold>\n                    <\/jats:p>\n                    <jats:p>This study establishes a therapeutic drug monitoring (TDM)\u2013based prediction model integrating CsA trough concentrations with key concomitant medications (azole antifungals, amphotericin B (AmB), and ursodeoxycholic acid) to estimate the individualized risk of CsA-associated liver injury in children with thalassemia after HSCT.<\/jats:p>\n                    <jats:p>\n                      <jats:bold>What is the clinical implication<\/jats:bold>\n                    <\/jats:p>\n                    <jats:p>This model provides a practical tool to support early risk stratification, optimize CsA dose adjustment, and guide individualized immunosuppressive and antifungal therapy, thereby improving medication safety in pediatric HSCT recipients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Cyclosporine A (CsA) is a cornerstone immunosuppressant after hematopoietic stem cell transplantation (HSCT) in children, but its narrow therapeutic window and large interindividual pharmacokinetic variability confer a substantial risk of drug-induced liver injury (DILI). This study aimed to develop a therapeutic drug monitoring\u2013driven predictive model for CsA-associated liver injury in pediatric thalassemia patients following HSCT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A retrospective cohort of 116 pediatric patients with thalassemia who underwent HSCT between January 2020 and June 2023 was analyzed. Clinical characteristics, laboratory indices, CsA trough concentrations, and concomitant medications were collected within the first 100 days posttransplantation. Least absolute shrinkage and selection operator regression was applied for feature selection, followed by multivariate logistic regression to identify independent predictors. A nomogram was constructed and internally validated using bootstrap resampling. Model performance was evaluated using the concordance index (C-index), receiver operating characteristic curve, calibration analysis, and decision curve analysis. The events-per-variable ratio was calculated to assess model stability. With 46 DILI events and 4 predictors in the final model, the events-per-variable exceeded 10, supporting adequate model robustness. Multicollinearity was assessed using variance inflation factors, with all values &lt;5.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      DILI occurred in 46 of 116 patients (39.7%). Four independent predictors were identified: CsA trough concentration 150\u2013250 ng\/mL (OR 5.84,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.001), CsA trough concentration &gt;250 ng\/mL (OR 30.05,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001), azole antifungal use (OR 24.27,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.003), and amphotericin B exposure (OR 3.66,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.042). Ursodeoxycholic acid showed a protective effect. The nomogram demonstrated excellent discrimination with a C-index of 0.858 and a bootstrap-corrected C-index of 0.823. The area under the receiver operating characteristic curve was 0.858, with good calibration and favorable net clinical benefit across wide probability thresholds in decision curve analysis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>A therapeutic drug monitoring\u2013driven nomogram integrating CsA exposure levels and key concomitant medications accurately predicts the risk of CsA-associated liver injury in pediatric thalassemia patients after HSCT. This model may support individualized immunosuppressive management and early prevention of hepatotoxicity in this high-risk population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001482","type":"journal-article","created":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T14:00:38Z","timestamp":1783519238000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Therapeutic Drug Monitoring\u2013Driven Prediction of Cyclosporine-Associated Liver Injury in Pediatric Thalassemia After Hematopoietic Stem Cell Transplantation"],"prefix":"10.1097","author":[{"given":"Fuli","family":"Qin","sequence":"first","affiliation":[{"name":"Department of Pharmacy, The First Affiliated Hospital of Guangxi Medical University, Nanning, China;"},{"name":"Guangxi Key Laboratory of Pharmaceutical Precision Detection and Screening, Nanning, China; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuhua","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The First Affiliated Hospital of Guangxi Medical University, Nanning, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiu'an","family":"Lan","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Guangxi Medical University Cancer Hospital, Nanning, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunxuan","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The First Affiliated Hospital of Guangxi Medical University, Nanning, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daohai","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The First Affiliated Hospital of Guangxi Medical University, Nanning, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanqi","family":"Shen","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The First Affiliated Hospital of Guangxi Medical University, Nanning, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiemei","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The First Affiliated Hospital of Guangxi Medical University, Nanning, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taotao","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The First Affiliated Hospital of Guangxi Medical University, Nanning, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongliang","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The First Affiliated Hospital of Guangxi Medical University, Nanning, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The First Affiliated Hospital of Guangxi Medical University, Nanning, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuangyi","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The First Affiliated Hospital of Guangxi Medical University, Nanning, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,7,8]]},"reference":[{"key":"R1-20260708","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.hoc.2017.11.006","article-title":"Clinical classification, screening and diagnosis for thalassemia","volume":"32","author":"Viprakasit","year":"2018","journal-title":"Hematol Oncol Clin North Am."},{"key":"R2-20260708","first-page":"272","article-title":"Alpha- and beta-thalassemia: rapid evidence review","volume":"105","author":"Baird","year":"2022","journal-title":"Am Fam Physician."},{"key":"R3-20260708","first-page":"339","article-title":"Alpha and beta thalassemia","volume":"80","author":"Muncie","year":"2009","journal-title":"Am Fam Physician"},{"key":"R4-20260708","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1080\/03630269.2021.2008960","article-title":"THALASSEMIA in ASIA 2021: thalassemia in Guangxi Province, People's Republic of China","volume":"46","author":"Chen","year":"2022","journal-title":"Hemoglobin"},{"key":"R5-20260708","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1111\/petr.12704","article-title":"Haploidentical hematopoietic stem cell transplantation for paediatric high-risk T-cell acute lymphoblastic leukaemia","volume":"20","author":"Xu","year":"2016","journal-title":"Pediatr Transpl."},{"key":"R6-20260708","doi-asserted-by":"crossref","first-page":"307","DOI":"10.4067\/S0716-97602012000300012","article-title":"Hematopoietic stem cell transplantation: clinical use and perspectives","volume":"45","author":"Barriga","year":"2012","journal-title":"Biol Res."},{"key":"R7-20260708","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.path.2023.04.007","article-title":"Liver pathology after hematopoietic stem cell transplantation","volume":"16","author":"Phansalkar","year":"2023","journal-title":"Surg Pathol Clin."},{"key":"R8-20260708","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1056\/NEJMoa041276","article-title":"Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia","volume":"351","author":"Laughlin","year":"2004","journal-title":"N Engl J Med."},{"key":"R9-20260708","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1038\/s41409-020-0899-0","article-title":"Financial impact of post-transplant complications among children undergoing allogeneic hematopoietic cell transplantation","volume":"55","author":"Ricci","year":"2020","journal-title":"Bone Marrow Transpl."},{"key":"R10-20260708","doi-asserted-by":"crossref","first-page":"187","DOI":"10.3747\/co.26.5033","article-title":"A general practitioner's guide to hematopoietic stem-cell transplantation","volume":"26","author":"Bazinet","year":"2019","journal-title":"Curr Oncol."},{"key":"R11-20260708","doi-asserted-by":"crossref","first-page":"489","DOI":"10.3389\/fimmu.2020.00489","article-title":"Diagnosis and treatment of VOD\/SOS after allogeneic hematopoietic stem cell transplantation","volume":"11","author":"Bonifazi","year":"2020","journal-title":"Front Immunol."},{"key":"R12-20260708","doi-asserted-by":"crossref","first-page":"15316","DOI":"10.1038\/s41598-022-19059-x","article-title":"Predicting the risk of acute kidney injury after hematopoietic stem cell transplantation: development of a new predictive nomogram","volume":"12","author":"Gan","year":"2022","journal-title":"Sci Rep."},{"key":"R13-20260708","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.trre.2014.08.001","article-title":"Liver disease after hematopoietic cell transplantation in adults","volume":"29","author":"Norvell","year":"2015","journal-title":"Transpl Rev (Orlando)."},{"key":"R14-20260708","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s43046-020-0020-1","article-title":"Liver disease during and after hematopoietic stem cell transplantation in adults: a single-center Egyptian experience","volume":"32","author":"Abdelbary","year":"2020","journal-title":"J Egypt Natl Canc Inst."},{"issue":"suppl 6","key":"R15-20260708","doi-asserted-by":"crossref","first-page":"s104","DOI":"10.7861\/clinmedicine.16-6-s104","article-title":"Drug-induced liver injury","volume":"16","author":"Katarey","year":"2016","journal-title":"Clin Med (Lond)."},{"key":"R16-20260708","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.bbmt.2013.02.019","article-title":"Risk factors associated with liver injury and impact of liver injury on transplantation-related mortality in pediatric recipients of allogeneic hematopoietic stem cell transplantation","volume":"19","author":"Radhakrishnan","year":"2013","journal-title":"Biol Blood Marrow Transpl."},{"key":"R17-20260708","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.2174\/0929867327666201006153202","article-title":"Chemistry and toxicity - a review","volume":"28","author":"Patocka","year":"2021","journal-title":"Curr Med Chem."},{"key":"R18-20260708","first-page":"185","article-title":"Consensus of Chinese experts on prevention and standardized treatment of drug-induced liver injury in patients with blood diseases","volume":"43","year":"2021","journal-title":"honghua Xue Ye Xue Za Zhi"},{"key":"R19-20260708","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1182\/blood-2002-06-1860","article-title":"Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation","volume":"101","author":"McDonald","year":"2003","journal-title":"Blood"},{"key":"R20-20260708","first-page":"889","article-title":"Chinese guideline for diagnosis and treatment of transfusion dependent beta-thalassemia","volume":"43","year":"2022","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"R21-20260708","first-page":"3221","article-title":"European guidelines for primary antifungal prophylaxis in adult haematology patients: summary of the updated recommendations from the European Conference on Infections in Leukaemia","volume":"73","author":"Maertens","year":"2018","journal-title":"J Antimicrob Chemother."},{"key":"R22-20260708","first-page":"92","volume":"44","year":"2023","journal-title":"Zhonghua Xue Ye Xue Za Zhi."},{"key":"R23-20260708","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1093\/jac\/dkw099","article-title":"Utility of voriconazole therapeutic drug monitoring: a meta-analysis","volume":"71","author":"Luong","year":"2016","journal-title":"J Antimicrob Chemother."},{"key":"R24-20260708","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1007\/s10096-013-1998-2","article-title":"Comparison of itraconazole, voriconazole, and posaconazole as oral antifungal prophylaxis in pediatric patients following allogeneic hematopoietic stem cell transplantation","volume":"33","author":"D\u00f6ring","year":"2014","journal-title":"Eur J Clin Microbiol Infect Dis."},{"key":"R25-20260708","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S0140-6736(21)00219-1","article-title":"Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial","volume":"397","author":"Maertens","year":"2021","journal-title":"Lancet"},{"key":"R26-20260708","doi-asserted-by":"crossref","first-page":"236","DOI":"10.37201\/req\/013.2023","article-title":"Recommendations on the use of azole antifungals in hematology-oncology patients","volume":"36","author":"Azanza","year":"2023","journal-title":"Rev Esp Quimioter."},{"key":"R27-20260708","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.3390\/pharmaceutics13111961","article-title":"The overview on the pharmacokinetic and pharmacodynamic interactions of triazoles","volume":"13","author":"Czyrski","year":"2021","journal-title":"Pharmaceutics"},{"key":"R28-20260708","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1093\/mmy\/myaa008","article-title":"Reasons for voriconazole prophylaxis discontinuation in allogeneic hematopoietic cell transplant recipients: a real-life paradigm","volume":"58","author":"Chan","year":"2020","journal-title":"Med Mycol."},{"key":"R29-20260708","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1007\/s10096-005-0080-0","article-title":"Adverse effects of antifungal therapies in invasive fungal infections: review and meta-analysis","volume":"25","author":"Girois","year":"2006","journal-title":"Eur J Clin Microbiol Infect Dis."},{"key":"R30-20260708","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s13181-010-0120-8","article-title":"An evaluation of hepatotoxicity and nephrotoxicity of liposomal amphotericin B (L-AMB)","volume":"7","author":"Patel","year":"2011","journal-title":"J Med Toxicol."},{"key":"R31-20260708","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1086\/431586","article-title":"The hepatotoxicity of antifungal medications in bone marrow transplant recipients","volume":"41","author":"Fischer","year":"2005","journal-title":"Clin Infect Dis."},{"key":"R32-20260708","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/S0953-6205(02)00065-1","article-title":"Amphotericin B and liver function","volume":"13","author":"Inselmann","year":"2002","journal-title":"Eur J Intern Med."},{"key":"R33-20260708","doi-asserted-by":"crossref","first-page":"3554","DOI":"10.1016\/j.transproceed.2014.06.065","article-title":"Prophylactic use of liposomal amphotericin B in preventing fungal infections early after liver transplantation: a retrospective, single-center study","volume":"46","author":"Antunes","year":"2014","journal-title":"Transpl Proc."},{"key":"R34-20260708","doi-asserted-by":"crossref","first-page":"975","DOI":"10.7326\/0003-4819-128-12_Part_1-199806150-00002","article-title":"Ursodiol prophylaxis against hepatic complications of allogeneic bone marrow transplantation. A randomized, double-blind, placebo-controlled trial","volume":"128","author":"Essell","year":"1998","journal-title":"Ann Intern Med."},{"key":"R35-20260708","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.bbmt.2006.09.012","article-title":"Systematic review of controlled clinical trials on the use of ursodeoxycholic acid for the prevention of hepatic veno-occlusive disease in hematopoietic stem cell transplantation","volume":"13","author":"Tay","year":"2007","journal-title":"Biol Blood Marrow Transpl."},{"key":"R36-20260708","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.bbmt.2015.09.024","article-title":"Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: risk factors and stratification, prophylaxis, and treatment","volume":"22","author":"Dalle","year":"2016","journal-title":"Biol Blood Marrow Transpl."},{"key":"R37-20260708","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1182\/blood-2001-12-0159","article-title":"Ursodeoxycholic acid for the prevention of hepatic complications in allogeneic stem cell transplantation","volume":"100","author":"Ruutu","year":"2002","journal-title":"Blood"},{"key":"R38-20260708","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.bbmt.2004.06.004","article-title":"A multiagent strategy to decrease regimen-related toxicity in children undergoing allogeneic hematopoietic stem cell transplantation","volume":"10","author":"Thornley","year":"2004","journal-title":"Biol Blood Marrow Transpl."},{"key":"R39-20260708","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4274\/tjh.2016.0450","article-title":"Current review of iron overload and related complications in hematopoietic stem cell transplantation. G\u00fcncel derleme: Hematopoietik k\u00f6k H\u00fccre Naklinde Demir Y\u00fcklenmesi ve i\u0307li\u015fkili komplikasyonlar","volume":"34","author":"Atilla","year":"2017","journal-title":"Turk J Haematol."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001482","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T14:00:43Z","timestamp":1783519243000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001482"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,8]]},"references-count":39,"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001482","relation":{},"ISSN":["0163-4356","1536-3694"],"issn-type":[{"value":"0163-4356","type":"print"},{"value":"1536-3694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,8]]},"assertion":[{"value":"2025-12-08","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-23","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}